Sutro Biopharma Inc
NASDAQ:STRO
Sutro Biopharma Inc
Total Current Assets
Sutro Biopharma Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sutro Biopharma Inc
NASDAQ:STRO
|
Total Current Assets
$182.1m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$28.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$19.9B
|
CAGR 3-Years
11%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Total Current Assets
$253.5m
|
CAGR 3-Years
29%
|
CAGR 5-Years
36%
|
CAGR 10-Years
13%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
Sutro Biopharma Inc
Glance View
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.
See Also
What is Sutro Biopharma Inc's Total Current Assets?
Total Current Assets
182.1m
USD
Based on the financial report for Sep 30, 2025, Sutro Biopharma Inc's Total Current Assets amounts to 182.1m USD.
What is Sutro Biopharma Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
-9%
Over the last year, the Total Current Assets growth was -55%. The average annual Total Current Assets growth rates for Sutro Biopharma Inc have been -19% over the past three years , -9% over the past five years .
